PHRM 864 Oncology Exam Questions and Answers A+ Graded (2025).

www.stuvia.com/user/BRAINSCAPE1




PHRM 864 Oncology Exam Questions
and Answers A+ Graded (2025)




Gefitinib, Erlotinib MOA - CORRECT ANSWER-type 1 reversible inhibitor of EGFR
tyrosine kinase

Gefitinib, Erlotinib Indication - CORRECT ANSWER-treatment of metastatic
NSCLC with EGFR exon 19 or 21 mutations

Gefitinib, Erlotinib Side Effects - CORRECT ANSWER-rash
diarrhea
fatigue

Afatinib MOA - CORRECT ANSWER-covalent inhibitor of ErbB receptors

Afatinib Indication - CORRECT ANSWER-treatment of metastatic NSCLC with
EGFR exon 19 or 21 mutations

Afatinib Side Effects - CORRECT ANSWER-rash
diarrhea
fatigue

Osimertinib MOA - CORRECT ANSWER-covalent inhibitor of EGFR with T790M
mutation

Osimertinib Indication - CORRECT ANSWER-treatment of metastatic NSCLC with
EGFR exon 19 or 21 mutation or T790M mutation

Lapatinib MOA - CORRECT ANSWER-reversible TKI of both EGFR and HER2

Lapatinib Indication - CORRECT ANSWER-treatment of HER2+ advanced breast
cancer (combination with capecitabine)

Lapatinib Side effects - CORRECT ANSWER-N/V/D
symptoms of CHF

Tucatinib MOA - CORRECT ANSWER-reversible TKI of HER2

, www.stuvia.com/user/BRAINSCAPE1




Tucatinib Indication - CORRECT ANSWER-treatment of HER2+ advanced breast
cancer (combination with capecitabine + trastuzumab)

Midostaurin MOA - CORRECT ANSWER-1st generation FLT3 inhibitor

Midostaurin Indication - CORRECT ANSWER-acute myeloid leukemia

Crenolanib MOA - CORRECT ANSWER-2nd generation FLT3 inhibitor

Crenolanib Indication - CORRECT ANSWER-acute myeloid leukemia

Quizartinib MOA - CORRECT ANSWER-type 2 FLT3 inhibitor for ITD

Quizartinib Indication - CORRECT ANSWER-acute myeloid leukemia

Imatinib MOA - CORRECT ANSWER-type 2 inhibitor of Abl tyrosine kinase

Imatinib Indication - CORRECT ANSWER-treatment of chronic myeloid leukemia

Imatinib Side Effects - CORRECT ANSWER-N/V
edema
neutropenia, thrombocytopenia

Ponatinib MOA - CORRECT ANSWER-inhibitor of Abl tyrosine kinase with T315I
mutation

Ponatinib Indication - CORRECT ANSWER-treatment of chronic myeloid leukemia

Alectinib MOA - CORRECT ANSWER-inhibitor of ALK

Alectinib Indication - CORRECT ANSWER-treatment of ALK+ metastatic NSCLC

Dabrafenib MOA - CORRECT ANSWER-BRAF V600 inhibitor

Dabrafenib Indication - CORRECT ANSWER-treatment of BRAF V600 mutant
melanoma or NSCLC

Trametinib MOA - CORRECT ANSWER-type 3 allosteric inhibitor of MEK 1/2

Acalabrutinib MOA - CORRECT ANSWER-covalent BTK inhibitor & Cys481

Acalabrutinib Indication - CORRECT ANSWER-treatment of B-cell lymphoma
(MCL & CLL)

Everolimus MOA - CORRECT ANSWER-inhibits mTORC1 but not mTORC2

Everolimus Indication - CORRECT ANSWER-treatment of advanced renal
carcinoma